Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Equities research analysts at Jefferies Group issued their FY2022 EPS estimates for shares of Celldex Therapeutics in a research report issued to clients and investors on Thursday. Jefferies Group analyst B. Amin expects that the biopharmaceutical company will post earnings of ($0.07) per share for the year.
Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Wednesday, March 7th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.08. The business had revenue of $3.50 million for the quarter, compared to analyst estimates of $1.49 million. Celldex Therapeutics had a negative return on equity of 44.64% and a negative net margin of 730.06%. The business’s revenue was up 87.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.30) EPS.
Shares of Celldex Therapeutics (CLDX) opened at $2.82 on Friday. The stock has a market capitalization of $393.24, a P/E ratio of -3.20 and a beta of 2.63. Celldex Therapeutics has a 52-week low of $2.20 and a 52-week high of $3.75.
Hedge funds and other institutional investors have recently modified their holdings of the business. Cubist Systematic Strategies LLC acquired a new stake in Celldex Therapeutics in the third quarter worth $101,000. OxFORD Asset Management LLP acquired a new stake in Celldex Therapeutics in the third quarter worth $122,000. Teacher Retirement System of Texas increased its position in Celldex Therapeutics by 325.0% in the fourth quarter. Teacher Retirement System of Texas now owns 43,253 shares of the biopharmaceutical company’s stock worth $123,000 after buying an additional 33,077 shares during the period. Voya Investment Management LLC increased its position in Celldex Therapeutics by 17.4% in the second quarter. Voya Investment Management LLC now owns 50,535 shares of the biopharmaceutical company’s stock worth $125,000 after buying an additional 7,499 shares during the period. Finally, MetLife Investment Advisors LLC acquired a new stake in Celldex Therapeutics in the fourth quarter worth $187,000. 57.55% of the stock is currently owned by hedge funds and other institutional investors.
About Celldex Therapeutics
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.